Scimega Research is pleased to announce the launch of its new Reverse Feasibility Resource Center
Scimega Research, (www.scimega.com) the experts in clinical oncology, is pleased to announce the launch of its newReverse Feasibility Resource Centre, a unique initiative that complements its highly successful Reverse Feasibility Program that matches the patient recruitment needs of U.S. oncology sponsors with the scientific interests of Canadian investigators and the treatment needs of their patients.
This microsite will enhance sponsor access to the program by providing regular updates that highlight Canada’s expertise in both early and late phase oncology trials. It currently features important information such as the number of oncology sites, key investigators, and catchment area size for each of the ten Canadian provinces.
Sponsors can sign up to receive free quarterly updates on the types of trials Scimega’s Reverse Feasibility Champions are looking to participate in. The Oncology Trial Needs Report for Canada will highlight the number of sites actively looking for trials, based on lines of treatment, tumor types and targets.
“The Reverse Feasibility Program was launched in 2009 to attract state-of-the-art clinical research to Canada,” said Denise Deakin, President & co-founder of Scimega Research. “It was founded on the premise that long-standing relationships between Scimega and top performing oncology sites could be leveraged by sponsors to maximize the performance and quality of their trials, while enhancing the overall clinical trial experience for both investigators and patients,” continued Ms. Deakin.
“Using this approach, we’ve seen as much as a 50% reduction is study start-up times, while meeting targeted patient recruitment objectives. It’s really proven to be win-win situation as sponsors are thrilled with the performance metrics, while clinicians and their patients are happy to take participate in well designed, cutting-edge trials. We’re hoping the new Resource Centre will help facilitate many more of these positive experiences.”
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Ponsegromab Significantly Improves Body Weight in Patients with Cancer Cachexia
September 17th 2024Results of a Phase II study of ponsegromab showed significant improvements in body weight, muscle function, and overall symptoms for patients with cancer cachexia, offering hope for a new targeted treatment.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.